OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas.

Trial Profile

OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Bevacizumab; Fosbretabulin
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 20 May 2010 Trial design data will be presented in aposter at the 2010 ASCO Annual Meeting, according to an OXiGENE media release.
    • 27 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top